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In the 18th century, Edward Jenner and Caleb Hillier Parry, two British physicians, independently noticed that coronary ossification was often present in patients dying of 'syncope anginosa'. 1 Coronary angiography opened the possibility of expanding these observations to living patients and offered revascularisation options. During surgery, it was often possible to modify the position of the distal coronary anastomoses to avoid calcified segments. In terms of percutaneous treatment, heavily calcified coronary lesions still represent a challenge for interventional cardiology, with a greater risk of immediate complications and late failure due to stent underexpansion and malapposition. 2 Good characterisation of calcium distribution with multimodal imaging and optimal lesion preparation, facilitated by the introduction of new dedicated devices, are essential for successful treatment of calcified coronary stenoses.
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Pathophysiology of the Calcified Coronary Plaque
When discussing artery calcification, it is appropriate to distinguish between peripheral and coronary calcifications. In the peripheral arteries of the lower extremities, medial calcification is often found, driven by the action of osteoblast-like cells and due to various factors, such as hypercalcaemia, high phosphate blood concentrations and increased parathyroid hormone concentrations.
Conversely, the mechanism underlying the development of atherosclerotic coronary calcification is different, with dysmorphic calcium precipitation driven by chondrocyte-like cells and linked to expression of inflammatory factors, such as cytokines released by tissue macrophages and foam cells. 5 It is likely that inflammation precedes calcification and plays an important role in its progression, with the two processes coexisting and promoting each other.
The primary cause of the calcification process in atheroma is the death of inflammatory cells and smooth muscle cells (SMCs), with macrophage-derived matrix vesicles also playing a role in this event.
An intense inflammatory response due to cholesterol deposits caught under the endothelium leads to the development of microcalcification over areas ranging in size between 0.5 and 15.0 mm. 6 The differentiation of several cell types (e.g. pericytes and vascular SMCs) promotes bone deposition and contributes to necrotic core formation because of the local degradation of collagen fibres. 7 The entire process is driven by the fusion of cell debris originating from SMC apoptosis, which then serves as a focus for calcium phosphate crystal formation. A lack of calcification inhibitory factors (e.g. matrix gammacarboxyglutamic acid protein, pyrophosphate, fetuin-A, osteopontin and osteoprotegerin) also plays a role in the imbalance between osteogenic and osteoclastic mechanisms. 8 Some drugs, such as phosphate binders or receptor activator of nuclear factor-kappaB ligand blockers, are under investigation to reverse or prevent vascular calcification. 7 Microcalcifications can only be detected histopathologically using special stains, such as von Kossa stain and Alizarin red.
Microcalcifications can coalesce into larger masses over time to form speckles and calcified sheets, detectable in vivo using CT or intravascular imaging. In addition to plaque rupture and erosion, the development of subintimal large protruding masses may be a possible cause of plaque destabilisation and thrombus formation, and has been detected in 5% of cases of unstable syndrome and ST-elevation MI.
This role of the protruding masses in plaque destabilisation is at odds with the common belief that the substitution of large necrotic cores in positively remodelled arteries with fibrocalcific tissue, also promoted by statin therapy, is a marker of plaque stabilisation.
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Coronary Calcification as a Predictor of Events
CT allows calculation of the coronary artery calcium score, an independent predictor of coronary events in both asymptomatic and symptomatic individuals, as confirmed by Budoff et al. in the 10-year results of the Multi-Ethnic Study of Atherosclerosis (MESA) study. [10] [11] [12] [13] [14] Spotty calcifications are associated with unstable plaques and acute coronary syndrome. 15 Coronary calcification is also a marker of advanced atherosclerosis and is correlated with multivessel coronary disease and the presence of complex lesions, including long lesions, chronic total occlusions and bifurcations. The SYNTAX score is a method of estimating the complexity of coronary disease. The location and severity of lesions are the main drivers of high scores. Heavy calcification, visible with fluoroscopy, is also considered, adding 2 points per lesion. [16] [17] [18] [19] In recent registries and meta-analyses, the prevalence of moderate and severe calcific coronary stenoses has been reported to range between 18% and 26%. [16] [17] [18] In these studies, severe calcific lesions were found to be associated with advanced age, systemic hypertension, dyslipidaemia and diabetes. Chronic kidney disease can also be associated with severe coronary calcification. As a consequence of a progressively aging population and an increase in these comorbidities,
we expect a higher frequency of severe coronary calcification in patients undergoing percutaneous coronary intervention (PCI) in coming years.
PCI of coronary calcified lesions is associated with major stent underexpansion and malapposition, with major periprocedural complications and, subsequently, a high rate of target lesion failure, restenosis or thrombosis. Consequently, calcified coronary lesions are a predictor of a worse clinical outcome, associated with higher mortality, major adverse cardiovascular events (MACE) and target vessel failure on multivariate analysis after correction for confounders. [19] [20] [21] These results were confirmed in a recent registry, 17 as well as in a pooled analysis in patients treated exclusively with a second-generation drugeluting stent (DES). 18 Late and very late stent thrombosis are also more frequent in patients with calcific stenosis.
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Calcium and Imaging Techniques
Coronary CT angiography (CCTA) is the most important non-invasive imaging technique used to detect calcium. Calcium is detected as an area of hyperattenuation, defined as an area of at least 1 mm 2 with >130 Hounsfield units or ≥3 adjacent pixels using the Agatston method. 22 The calcium score is the sum of all coronary calcified lesions (excluding calcium in the valve or aorta) and is a strong prognostic factor for clinical events in the mid to long term in asymptomatic individuals. 11, 14, 15 CCTA is able to characterise coronary plaques; in particular, CCTA can detect spotty calcification, which is one of the four signs of vulnerable plaques (i.e. low CT attenuation, remarkable positive remodelling, spotty calcification and the napkin-ring sign).
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CCTA is also a valuable tool in planning PCI because it allows accurate identification of calcium in coronary lesions and localisation of calcium along coronary vessels, improving procedural success.
Coronary angiography often underestimates calcium, its grading is not accurate and calcium depth within the plaque is not assessed. 4 Moderate calcification is defined as radiopacity observed only during the cardiac cycle before injection of contrast medium. Severe calcification is defined as radiopacity observed without cardiac motion, visible on both sides of the arterial lumen, as a double track. 
Percutaneous Coronary Intervention of Complex Calcified Coronary Lesions
Either a transfemoral or transradial approach can be used in PCI for heavily calcified lesions, with the choice depending primarily on operator experience. Support wires, buddy wires, guide extensions, lesion predilatation and anchoring of the guide catheter with inflation of a second balloon in a side branch or distal vessel are possible options for the treatment of calcified coronary stenoses. 27, 28 When successful treatment cannot be obtained using these options, a dedicated device should be used for adequate lesion preparation ( Table 2) . kPa and a rated burst pressure of 3,546 kPa, but the balloon was tested calcified lesions or other lesions that cannot be dilated. In the past, it was often used for lesion preparation before bioresorbable vascular scaffold (BVS) implantation or to expand the BVS fully, given the small increases in diameter (<0.5 mm) stated by the manufacturer. 31, 32 In restricted clinical experience, the OPN NC balloon successfully treated >90% of undilatable lesions compared with a conventional NC balloon with a 0.9% rate of coronary rupture. 33 The OPN balloon is compatible with 0.014 inch wires and 5 Fr access, but it has a high profile (0.028 inches), although this is better than scoring and cutting balloons, and so it is difficult to recross or reuse after inflation.
Cutting and Scoring Balloons
The Flextome Cutting Balloon (Boston Scientific), introduced in 1991, is available in monorail or over-the-wire catheter, with the most recent iteration (Wolverine) improved in terms of profile and flexibility.
The Flextome Cutting Balloon is available in diameter sizes ranging from 2.0 to 4.0 mm (in 0.25 mm increments) and lengths of 6, 10 or 15 mm. 34 On a cutting balloon, three or four metal microblades are placed longitudinally on the surface of the balloon and the balloon works by cutting the media with radial incisions, thus reducing elastic recoil and minimising neointima proliferation. The microblades also prevent balloon slippage, which is particularly helpful for in-stent restenosis due to intimal hyperplasia. 35 Initial clinical experience 
with cutting balloon angioplasty appeared favourable because it achieved more lumen enlargement compared with traditional balloon angioplasty. 35 However, a later large randomised trial showed similar acute procedural success in patients with de novo undilatable lesions treated with cutting balloon or conventional balloon angioplasty, a similar binary restenosis rate at 6 months between the two groups (31.4% versus 30.4%, respectively; p=0.75) and a significantly higher perforation rate in the cutting angioplasty group (0.8% versus 0%; p=0.03). 41, 42 In a feasibility trial, the AngioSculpt balloon was used for the treatment of de novo lesions prior to BMS implantation and showed very high procedural success and a target lesion revascularisation rate of 10% at 6 months. 43 These results were confirmed in an observational study, in which 37 patients treated with AngioSculpt before stent implantation were compared to 145 patients treated with direct stenting and 117 patients with traditional plain old balloon angioplasty before stent implantation.
IVUS assessment showed greater stent expansion in the AngioSculpt group than in the other two groups (89% versus 74% of vessels with an area >5.0 mm 2 , respectively).
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The NSE Alpha scoring balloon (B Braun) has three triangular flexible nylon elements on the balloon surface attached only at the proximal and distal edges of the balloon. Promising results for predilatation of severe calcified lesions were shown with the leopard-crawl technique. 45 The Scoreflex (Orbus Neich) is a semicompliant balloon with two fixed
Nitinol wires on opposite sides of the balloon surface. 46 
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Rotational Atherectomy
RA was introduced more than 30 years ago to debulk and modify atherosclerotic plaques as an alternative or adjunctive strategy to percutaneous balloon angioplasty. 49 Although initial positive experiences with RA showed short-term lumen enlargement, there was also a high rate of target lesion revascularisation due to cell proliferation and restenosis. 50 In the DES era, in-stent restenosis decreased markedly; consequently, RA was reserved for lesion preparation before stent implantation in the case of heavily calcified 48 In that study, a greater success rate was achieved with RA than with modified balloons (98% versus 81%, respectively), driven primarily by delivery failure of the bulky cutting or scoring balloons, with no significant difference in late lumen loss at 9 months. 48 Periprocedural complications were low and similar in the two groups, probably due to highly experienced operators. 48 The Rotablator System (Boston Scientific) is made up of three components: a nickel-plated elliptic burr coated with diamond microscopic crystals that is available in sizes ranging from 1.25 to 2.50 mm diameter; a single advancer that can transmit rotational speed to the burr and is connected with a gas-driven turbine; and a control console and foot pedal (in most recent models, the latter has been replaced by an activator in the connecting handle). 59 In recent years, a reduction in burr size and a more standardised protocol with low rotation speeds have decreased periprocedural complications. When the burr is proximal to the lesion, rotablation can be started with short burr runs (<20 seconds) at low rotational speed (135,000-180,000 rpm). Small burrs (1.25 and 1.50 mm; burr-to-artery ratio=0.6) are adequate in most lesions as an initial approach, but occasionally it may be necessary to increase burr size with a step-up approach. [64] [65] [66] • A single-sized crown of 1.25 mm is used in OA to treat vessels with a diameter of 2.5-4.0 mm, regulating rotational speed.
• Two rotational speeds, namely 80,000 rpm (low speed) and 120,000 rpm (high speed), allow different ablation of vessels with different diameters, with the high speed creating greater centrifugal force and a higher orbital diameter.
• In OA, the crown rotation is less concentric; therefore, in aortoostial lesions, where there is a large transition from large to small lumen, OA should be used with caution.
• ViperWire Advance (Cardiovascular Systems) is a dedicated wire for the Diamondback 360 Coronary OA System and is available in one version only (no floppy or extra support versions, as available for the RotaWire) and has 0.012 inch profile.
• In OA, a bidirectional atherectomy is performed, not only anterograde as in RA, with a consequent decrease in crown entrapment.
• Continuous flow of blood and saline solution or other lubricant solutions (e.g. soybean oil, egg yolk) during ablation minimises thermal injury and potentially decreases no-reflow and periprocedural complications.
• The smaller microparticles created by OA (2 µm) have a minimal effect on the microcirculation.
• Device activation is simpler and faster for OA than RA (one-touch activation and 2 minutes, respectively).
Some innovative components of the OA system are now available for clinical use in Japan or for research applications. The Coronary OA Micro Crown (Cardiovascular Systems) has a new diamond-coated tip to better reach the target lesion and a 1.25 mm eccentric crown that allows it to rotate at lower speeds and create an orbit similar to the Classic Crown, which, instead, is located concentrically on an eccentric bump. In addition, a new ViperWire and GlideAssist system are available to easily track the OA device through tortuous coronary vessels.
OCT has been used to demonstrate the mechanism of action of OA, revealing deeper and longer cuts in calcific plaques with OA than RA. In addition, OA modified calcified plaques more than RA, with consequently better stent apposition and expansion. 54 The Orbital Atherectomy System in treating de novo calcified coronary lesions (ORBIT I) study was the first-in-human trial to evaluate the safety and performance of OA in 50 patients at two Indian centres,
showing a procedural success rate of 94% and a MACE rate of 8% at 30 days. 68 The ORBIT II study is a non-randomised trial, enrolling 443 patients with severe calcified lesion in 49 US hospitals. 69 ORBIT II showed high procedural success (98.6% of patients with <50% residual stenosis) and good outcomes, namely 4.4% cardiac deaths at 2 years, 8.1% target lesion revascularisation at 2 years and low periprocedural complications (slow flow <1%, coronary dissections 5.9%). Lee et al.
reported real-world data for 458 patients treated with OA in three US hospitals, confirming positive results at 1 year. 70 The Diamondback 360 Micro Crown has recently been proposed as a technological advancement; it is able to obtain a higher sanding area with lower rotational speed (50,000-70,000 rpm). This new device was used in the Coronary Orbital Atherectomy System Study (COAST), which found that 85% of patients were free of MACE at 30 days. complex coronary artery lesions reported a procedural success rate of 93% and both minor and major periprocedural complications. 76, 77 In the context of coronary calcified lesions, the use of ELCA is limited to that of a 'bail-out' strategy, when lesions are uncrossable for dedicated balloons or for the RotaWire or ViperWire, and its use is limited to a restricted number of centres. A combination of ELCA and RA was recently described (the RASER technique). 78 The main application of The mechanism of action was described by Ali et al., who used OCT in 31 patients with severe coronary calcified lesions treated with IVL. 81 In that study, lumen enlargement and single or multiple calcium fractures were observed after IVL in 43% of patients. The Shockwave Coronary Rx Lithoplasty ® Study (Disrupt CAD I), a single-arm feasibility trial, enrolled 60 patients with calcified coronary artery disease treated with IVL across seven countries. 82 The primary endpoint (residual diameter stenosis <50% after stent implantation without in-hospital MACE) was achieved in 98.5% of patients (residual stenosis mean ± SD: 13.3 ± 11.6%) and acute luminal gain was 1.7 ± 0.6 mm. Analysing data from that study indicated that the technique appeared safe with no major periprocedural complications (no residual dissections, no perforation, no slow flow or no-reflow).
The Disrupt CAD II trial completed enrolment of 120 patients in 15 hospitals in April 2019. 83 Preliminary data indicate successful delivery of the IVL balloon in all patients, with 34% facilitated by predilation. The post-IVL angiographic acute luminal gain was 0.8 ± 0.5 mm and residual stenosis was 29 ± 12%, which further In this context, we believe that IVL has the potential of more widespread adoption because of its efficacy, at least in concentric calcified lesions, safety (with a short learning curve), low periprocedural complications and no risk of coronary perforation. In light of these changes, we propose a new algorithm to approach the treatment of coronary calcified lesions after preliminary characterisation based on multimodal imaging. OCT is certainly the preferred intravascular imaging technique for calcified coronary lesions, but it is not feasible in some cases, such as in moderate to severe renal failure or in severe stenoses. In such cases, IVUS can quantify calcium arc and calcium length, but not calcium depth.
For this reason we have modified the OCT score proposed by Fujino et al. 26 to enable the use of OCT with IVUS, adding an adjunctive point for lesions with a calcium arc >270° and calcium length >5 mm because, based on our experience, deeper calcified lesions have concomitantly more concentric calcium and longitudinally extended calcium. In addition, another point has been added for lesions with an arc >270° because, based on the literature, the efficacy of IVL was greater in these lesions. Analysing these parameters, a decisional algorithm was proposed to guide the interventional cardiologist to choose the most appropriate device (Figure 2) . In case of unsuccessful or partially successful treatment, more devices can be used in sequence, as reported in a recent case of RotaTripsy treatment (a combination of RA and IVL).
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Conclusion
The problem of heavily calcified coronary lesions will increase in the future because of an aging population and increased rates of diabetes and chronic renal disease. An approach based on multimodal imaging techniques and the use of dedicated devices is key to improve patient outcomes. Further data will be needed to confirm the efficacy of these new, dedicated devices on long-term clinical outcome. 
